A comprehensive evaluation of BChE and AChE inhibition potency accompanied with a docking study enabled the identification of BChE selective inhibitors from which cinconidine CD-(pBr) can be pointed out as a lead molecule for further optimization for possible use in the treatment of neurodegenerative diseases, like Alzheimer’s disease. This evidence concerns the gene ACHE and Alzheimer disease.